Search results for " Subarachnoid Hemorrhage"

showing 2 items of 12 documents

Hemodynamic Monitoring in Patients With Subarachnoid Hemorrhage: A Systematic Review and Meta-Analysis

2020

Aneurysmal subarachnoid hemorrhage (aSAH) often causes cardiopulmonary dysfunction. Therapeutic strategies can be guided by standard (invasive arterial/central venous pressure measurements, fluid balance assessment), and/or advanced (pulse index continuous cardiac output, pulse dye densitometry, pulmonary artery catheterization) hemodynamic monitoring. We conducted a systematic review and meta-analysis of the literature to determine whether standard compared with advanced hemodynamic monitoring can improve patient management and clinical outcomes after aSAH. A literature search was performed for articles published between January 1, 2000 and January 1, 2019. Studies involving aSAH patients …

medicine.medical_specialtySubarachnoid hemorrhageCentral Venous PressureHemodynamicslaw.inventionBrain Ischemia03 medical and health sciences0302 clinical medicineRandomized controlled trial030202 anesthesiologylawhemodynamicInternal medicinemedicineHumansCardiac Outputbusiness.industryHemodynamic MonitoringCentral venous pressureSubarachnoid Hemorrhagemedicine.diseaseIntensive care unitConfidence intervalmonitoringAnesthesiology and Pain Medicineblood volumeRelative riskMeta-analysisCardiologySurgeryNeurology (clinical)aneurysmal subarachnoid hemorrhagebusiness030217 neurology & neurosurgery
researchProduct

Erythropoietin for Subarachnoid Hemorrhage: Is There a Reason for Hope?

2011

I b S a r a S ubarachnoid hemorrhage (SAH) associated with a ruptured cerebral aneurysm remains a source of significant morbidity and mortality, not only from the initial hemorrhage but lso from the delayed complications, such as cerebral vasospasm ften severe enough to induce irreversible changes in cerebral erfusion. Several drugs have been developed that have the otential to limit cerebral vasospasm and delayed ischemic eurologic deficit, thus improving outcome for patients. Howver, although numerous agents that can prevent arterial narrowng and/or block the excitatory cascade of events leading to schemic neuronal death in experimental conditions, there is still o pharmacologic agent tha…

medicine.medical_specialtySubarachnoid hemorrhageErythropoietin subarachnoid hemorrhageBlood volumeAneurysm RupturedNeuroprotectionAneurysmCerebral vasospasmInternal medicinemedicineErythropoietin; Neuroprotection; Subarachnoid hemorrhageHumansSubarachnoid hemorrhageErythropoietinSettore MED/27 - Neurochirurgiabusiness.industryEpoetin alfaPharmacologic Agentmedicine.diseaseRecombinant ProteinsNeuroprotectionEpoetin AlfaNeuroprotective AgentsErythropoietinCardiologySurgeryNeurology (clinical)businessmedicine.drug
researchProduct